Type 1 diabetes (T1D) is associated with an increased fracture risk, which is present at young and old age. Reductions in bone mineral density do not explain the increased fracture risk. Novel scanning modalities suggest that structural deficits may contribute to the increased fracture risk. Furthermore, T1D may due to insulinopenia be a state of low bone turnover. However, diabetes complications and comorbidities may influence fracture risk. Patients with T1D are fearful of falls. The diabetes related complications, hypoglycemic events, and antihypertensive treatment may all lead to falls. Thus, the increased fracture risk in T1D seems to be multifactorial, and earlier intervention with antiosteoporotic medication and focus on fall prevention is needed. This systematic review addresses the epidemiology of fractures and osteoporosis in patients with T1D and the factors that influence fracture risk.
Introduction
Type 1 diabetes (T1D) is a condition with insulinopenia and well-known complications such as retinopathy, neuropathy, and nephropathy. During recent years, T1D has been linked to a new complication: Bone fragility. Osteoporosis is a condition related to an increased fracture risk. Based on estimates from the United States, the prevalence of T1D is 0.5 % and more common in young adults compared to type 2 diabetes (T2D), 1 whereas the prevalence of osteoporosis is 10.3% and most common in the elderly. 2 Based on prevalences,a small overlap between T1D and osteoporosis would be expected, however, recent research reports high fracture rates in patients with T1D compared to non-diabetes individuals, thus fracture rates may not be explained by classical osteoporosis. This review addresses the epidemiology of fractures and bone fragility in patients with T1D and elucidates the factors that may influence fracture risk.
Methods
A systematic literature search was performed on the 17 th of June 2019 using the database Medline at Pubmed. The search terms were "type 1 diabetes and fracture" and "type 1 diabetes and osteoporosis" leading to 624 hits. Furthermore, the reference list of systematic reviews and meta-analysis were examined. In total, 63 studies were included in the systematic review which all investigated bone fragility or mechanisms of bone fragility in patients with type 1 diabetes.
Epidemiology of Fractures in Type 1 Diabetes
Meta-analyses of observational studies have linked T1D to an increased risk of fractures compared with non-diabetes individuals. In the meta-analysis by Vestergaard, 3 the risk of a hip fracture was 7 fold increased in T1D compared to individuals without diabetes. This estimate is similar to the findings of Janghorbani et al, 4 where a 6 fold increased risk of hip fracture was found. In the metaanalyses, the age of the participants ranged from mean ages of 20 to 60 years. In a more recent cohort study using The Health Improvement Network (THIN) database, Weber et al reported increased risks of any fracture with HRs of 2.03 and 2.18 for women and men with T1D compared to individuals without diabetes, respectively. 5 Furthermore, in this study 6 the risk of hip fracture was increased in women at all ages and in men from age 30 and older. Shah et al evaluated 14 observational studies in a meta-analysis and reported that the risk of any fracture is 3 fold increased in patients with T1D compared to individuals without diabetes, but only 1.8 fold increased in men and 4.1 fold increased in women. 7 A more recent metaanalysis restricted the analysis to relatively young patients with T1D aged 18-50 years and reported a 1.9 fold increased risk of any fracture and a 4.4 fold increased risk of hip fracture in patients with T1D compared to individuals without diabetes. 8 Results from the previously mentioned metaanalyses are supported by more recent cohort studies: Hamilton et al reported a 7.11 increased hip fracture risk for patients with T1D compared with individuals without diabetes, but a 5 fold increased fracture risk when comparing patients with T1D with patients with T2D. 9 Notably, the study is limited by a low number of included patients with T1D (n=121), however, the study has a relatively long follow up of 14.5 years. 9 A cohort study using the Danish National Patient Registry provided more modest fracture risk estimates, with a 2.4 fold increased hip fracture risk and 2 fold increased upper extremity fracture risk. 10 Also, a cohort study using the Scottish national registries reported a 3.5 fold and a 3.3 fold increased risk of hip fracture in women and men with T1D compared to the general population, respectively. 11 Less is known about vertebral fractures in patients with T1D, however a study evaluated 82 patients with T1D and 82 controls by vertebral fracture assessment (VFA) with subsequent confirmation by x-ray, and reported a prevalence of vertebral fractures of 24% and 6%, respectively. 12 Another study by Jensen et al reported a 2.2 fold increased risk of spinal fractures in T1D compared with patients without diabetes, however this study is based solely on registry data where subclinical vertebral fractures are susceptible to nonregistration. 10 Based on the evidence available, patients with T1D have an increased risk of fracture during their entire life. The relative risk seems to be constant throughout life, although in absolute numbers most fractures occur at older age where the total fracture burden in the general population is greatest.
Bone Mineral Density in Type 1 Diabetes
One explanation of the increased bone fragility in patients with T1D is a decreased BMD and thereby classical osteoporosis. The meta-analysis by Vestergaard reported decreased BMD at the lumbar spine (ls) and hip in patients with T1D compared to individuals without diabetes, corresponding to Z-scores of −0.22 and −0.38, respectively. 3 A more recent meta-analysis by Shah et al including 16 studies reported no differences in BMD at the ls in patients with T1D compared to individuals without diabetes. 13 In this meta-analysis, however, the femoral neck (fn) BMD was decreased by 0.055 g/cm 2 , which corresponds to a Z-score of −0.55 assuming the standard deviation is 0.1. The decreased BMD is apparent in both male and female patients with T1D. 14 Patients with T1D have lower BMD compared with patients with T2D, 15 hence, the reduced BMD is a unique feature of T1D and is not due to any shared risk factors with T2D. Furthermore, BMD seems to be relatively stable in T1D irrespective of disease progression: A recent study reported reduced levels of fn BMD in patients with T1D duration of more than 50 years, whereas ls BMD was increased. 16 Likewise, Hamilton et al followed 48 patients with T1D for 10 years and found that BMD at the spine, fn, and forearm remained stable when adjusted for body mass index (BMI). 17 Hence, changes may occur early in T1D as children with T1D have decreased fn BMD with a Z-score of −0.57, similar to previously described metaanalysis. 13, 18, 19 In addition, children with T1D and glycated hemoglobin A1c (HbA1c) ≥7.5% have lower bone mass accrual during twelve months 18 and adolescents with T1D and HbA1c ≥8.0% have lower total body BMD compared to those with better glycemic control. 20 The early onset of low BMD in T1D may be due to calcium loss, as 25% of young women with T1D had greater urinary calcium excretion and less calcium retention in a study that used a dual stable calcium isotope to evaluate calcium intake and excretion. 21 Furthermore, insulinopenia in T1D may impact bone accrual (see the section Bone turnover in Type 1 diabetes for details). Thus, BMD changes seem to occur early in life in T1D.
However, the reduced BMD does not fully explain the increased risk of fracture in patients with T1D. 3 In T1D, the association between low BMD and fracture incidence has not been investigated, thus it is uncertain to which extent the small reduction in BMD influence fracture risk. Furthermore, the fracture risk assessment (FRAX) tool, which uses BMD among other risk factors to determine a 10-year fracture risk, has not been validated in cohorts of patients with T1D. However, a review by Hough et al provided insights of similar expected fracture rates in patients with and without T1D when applying the FRAX tool. 22 Thus, current fracture predictors underestimate the burden of fractures for patients with T1D, as illustrated by Figure 1 . Development of fracture prediction strategies is needed in T1D.
Bone Turnover in Type 1 Diabetes
Another mechanism underlying bone fragility may be an altered bone turnover. Diabetes is characterized by a state of low bone turnover. 23, 24 This characterization is mainly based on measurements of bone turnover markers in plasma or serum. In a meta-analysis, we found that levels of the bone resorption marker C-terminal cross-link of collagen (CTX) and the bone formation marker osteocalcin were decreased in T1D compared to individuals without diabetes. 23 Interestingly, levels of tartrate resistant acid phosphatase (TRAP) and of procollagen type 1 amino terminal propeptide (P1NP) were similar in patients with T1D compared with non-diabetes individuals but lower in patients with T2D compared to individuals without diabetes. However this may be due to a relatively low number of included studies that report on T1D (n=3 for TRAP and n=2 for P1NP). 23 Further, Vitamin D levels were reduced in patients with T1D compared with non-diabetes individuals. 24 A meta-analysis on levels of circulating bone turnover markers in children and adolescents with T1D also reported decreased levels of osteocalcin compared to individuals without diabetes whereas data were inconclusive for CTX and P1NP, 25 although, levels of P1NP tended towards being lower and levels of CTX towards being higher in T1D compared to individuals without diabetes. 25 A more recent study reported lower levels of bone specific alkaline phosphatase and CTX in children with T1D compared to healthy children. 26 In the 10-year follow up study by Hamilton et al, reported that men with T1D had lower levels of P1NP and osteocalcin after 10 years compared with baseline, 17 however this drop in bone formation markers is more likely to be an agerelated phenomenon than due effects of T1D. 27 In a study of the diurnal variations in bone turnover markers, levels of P1NP and osteocalcin were significantly lower in patients with T2D compared to individuals without diabetes, whereas results were non-significant for T1D. 28 Similarly, in a cross-sectional study comparing patients with T1D and T2D, levels of P1NP and osteocalcin were lower in T2D compared with T1D. 29 However, in the diurnal study, the bone formation markers tended to being lower in T1D compared with individuals without diabetes, and the lack of significance for the results may be due to low study power (participant n=5 in each group). 28 Levels of CTX, osteocalcin, and P1NP are stable during addition of glucose to blood samples, 24 thus, analytical factors do not explain the measured low levels of bone turnover markers. In our meta-analysis, the levels of circulating sclerostin were increased in patients with T1D compared with non-diabetes controls, and this may explain the lower bone turnover. Further, the levels of circulating osteoprotegerin and Receptor activator of nuclear factor kappa-B ligand (RANKL) were similar in T1D and individuals without diabetes. 23 A low bone turnover should optimally be confirmed by bone tissue biopsies. However, available data from bone tissue biopsies is sparse for patients with T1D. Based on the largest published study, T1D is a state of normal bone turnover. However the interpretation of the study is limited by very few biopsies (n=18), and that the participants had a well-controlled glycemic status. 30 Only one other bone biopsy study with T1D patients is available, however it reports diabetes patients as a whole with few patients with T1D compared to T2D (one out of six). 31 Thus, based on current evidence mainly based on cross-sectional studies where studies using bone turnover markers are more abundant; T1D is a state of low bone turnover.
A possible mechanism of low bone turnover may be hyperglycemia. 29 However, neither fluctuations in glucose during 24 hours 28 nor clamps with hypoglycemia and hyperglycemia 32 alter the levels of CTX or P1NP in patients with T1D. During a meal or an oral glucose tolerance test, levels of bone turnover markers decrease in healthy individuals and in patients with T2D. 33, 34 The influence of meals on bone turnover was similar between T1D, T2D and controls based on the diurnal study. 28 Insulin does not alter the levels of CTX or P1NP in T1D, 32 which has been confirmed by Basu et al. 35 However, insulinopenia in T1D may contribute to a low bone formation as insulin is a bone anabolic agent, 36 and bone turnover was decreased in a mouse model of insulinopenia but restored by insulin treatment. 37 Another mouse model of insulinopenia reported decreased levels of osteocalcin and RUNX2 with concomitant low insulin levels. 38 The low bone turnover caused by insulin deficiency possibly occurs over time and may not be detected in studies with acute changes in insulin levels as described above. 32, 35 As meals influence bone turnover, gastro-intestinal hormones may influence bone turnover in patients with T1D. A GIP infusion decreased the levels of CTX but not P1NP in patients with T1D. 32 The evidence of the incretin response in T1D is conflicting, but both GLP-1 and −2 have been suggested to impact bone turnover. 39 The diurnal study showed lower levels of GLP-2 in patients with T1D compared with T2D, and levels of GIP also tended to being lower in patients with T1D 28 compared with T2D. In T1D, both bone formation and bone resorption seems to be reduced but GLP-2 is mainly related to a decreased bone resorption and GLP-2 does not seem to impact bone formation. 40 Although insulinopenia and gastrointestinal hormones may influence bone turnover in T1D, the etiology of a reduced bone turnover remains unknown.
Bone Structure in Type 1 Diabetes
Microarchitectural changes may also impact the bone fragility in patients with T1D and recently more sophisticated scanning techniques have been developed. High Resolution peripheral Quantitative Computed Tomography (HRpQCT) is a technique that allows for in vivo measurement of bone microarchitecture in the tibia and radius. Few studies have evaluated this technique in T1D. A study by Shanbhogue et al compared 55 patients with T1D with 55 individuals without diabetes and found decreased trabecular thickness, increased trabecular separation, and decreased trabecular bone volume at the tibia and decreased trabecular thickness, and decreased trabecular bone volume, trabecular thickness and cortical thickness at the radius in patients with T1D and microvascular complications compared to individuals without diabetes. However, the findings were not present in patients with T1D without microvascular complications. 41 A study by our group compared 52 patients with T1D with 67 patients with T2D 15 and found similar characteristics of the trabecular compartment in patients with T1D and T2D when using HRpQCT. However, tissue stiffness at the tibia was lower in T1D compared with T2D. Notably, in contrast to the study by Shanbhogue et al, no association was present between microvascular complications and bone microarchitecture. 15 A study applying magnetic resonance imaging (MRI) showed increased trabecular separation and decreased trabecular number and trabecular bone volume at the tibia in 30 patients with T1D compared to 28 healthy individuals. The reduction in trabecular bone volume was most pronounced in individuals with retinopathy. 42 Taken together, these studies suggest alterations of the trabecular compartment. This is consistent with another study evaluating trabecular bone score (TBS) in T1D that reported lower TBS in patients with T1D compared to individuals without. 43 Another study reported borderline significantly (p=0.075) decreased TBS in patients with T1D compared to controls, but patients with T1D with prevalent fractures had lower TBS compared to patients with T1D without fracture. 44 Finally, a single study reported low cortical BMD measured by quantitative CT (QCT) at the ls in children and adolescents with T1D compared to healthy age-matched individuals. 45 These studies with advanced techniques are suggestive of structural changes beside what is explained by BMD in patients with T1D. However, only few studies with relatively small sample sizes are available. Whether structural changes depend on microvascular complications in T1D is unknown. The hip primarily consists of cortical bone and is most prone to fracture in T1D therefore it is notable that the structural deficits primarily are from the trabecular compartment. HRpQCT, QCT, MRI, and TBS are all novel technologies but with limited evidence both in the general population and especially in type 1 diabetes. Further research is warranted to evaluate whether the structural changes that can be detected by these techniques may explain the increased fracture risk in patients with T1D.
Impact of Hyperglycemia and AGEs on Bone Strength and Fracture Risk
Hyperglycemia may contribute to the bone fragility in T1D. Long-term hyperglycemia and oxidative stress may negatively impact bone strength by the production of advanced glycation endproducts (AGEs). It has been hypothesized that non-enzymatic cross-links are built into the collagen structure of the bone, thereby creating immature bone that is more fragile than normal bone. 46 Furthermore, the accumulation of AGEs seems to decrease bone formation in a rat model. 47 In a T1D mice model, microspectroscopy showed that AGEs accumulate in the bone and that bone strength is decreased. 48 In bone tissue biopsies from five patients with T1D and fracture, five patients with T1D and no fracture, and five healthy individuals, the levels of the AGE, pentosidine, were increased in patients with T1D and fracture compared to the other two groups. 49 Furthermore, patients with T1D and fracture had increased mineralization. 49 Thus in T1D, accumulations of AGEs may promote fractures, whereas the evidence for hyperglycemia as a fracture predictor is weaker. High levels of circulating pentosidine and HbA1c are associated with prevalent fractures, 50 where each percentage increase in HbA1c increases the OR for any fracture by 1.9. High levels of HbA1c is also associated with fragility fractures with an OR of 4.19 (for each percentage increase) and associated with multiple fractures in patients with T1D. 16, 51 A cohort study by Thayakaran et al reported an increased fracture risk with increasing HbA1c, although with a more modest risk increase of 1.01 per mmol/mol increase. 52 Although it is tempting to conclude that hyperglycemia may explain the increased fracture risk, other studies report no association between HbA1c and fracture, 53, 54 and the available data for patients with T1D is limited. The hypothesis of bone fragility due to hyperglycemia and development of AGEs is based on limited evidence and needs to be confirmed in both mechanistic studies and cohort studies.
Influence of Complications and Comorbidities on Fracture Risk
Diabetes-related complications may influence fracture risk, as neuropathy may lead to falls, 55, 56 retinopathy to decreased vision and falls, 57, 58 and nephropathy to renal osteodystrophy. 59 In T1D, the association is uncertain between diabetes-related complications and fracture risk. Some studies report increased fracture risk in patients with neuropathy, 51 retinopathy, 51 and nephropathy, 60 whereas others report no increased risk in patients with neuropathy, 9,52,53,60 retinopathy 9,52,53,60 and nephropathy. 9 One study reported increased fracture risk in patients with T1D and no complications. 60 Although the association between diabetes complications and fracture risk remains controversial, a study reported that 41% of patients with T1D are fearful of falls, and that the main contributors to falls are neuropathy and hypoglycemia. 61 A severe limitation to the studies assessing diabetes complications, falls, and fracture risk is that the data is mainly collected through registries and questionnaires, and therefore patients may be misclassified by both diabetes diagnosis (e.g. type 2 instead of type 1), falls (underestimation of actual number of falls), and fracture (date and site of fracture) in these studies.
Besides diabetes-related complications, T1D is linked to several other diseases. As a disease with an autoimmune component, other autoimmune diseases are more common in patients with T1D. T1D is associated with thyroid disease and celiac disease. 62 Both hypothyroidism and hyperthyroidism are associated with an increased fracture risk 63 and celiac disease is associated with an increased fracture risk in patients with T1D. 54 A study by Dhaliwal et al reported data on 756 patients with T1D and found a borderline significant association between fractures and celiac disease (p=0.06). 53 T1D is also linked to other autoimmune conditions such as rheumatoid arthritis, which is also associated with an increased fracture risk. 64, 65 Pancreatitis may cause endocrine dysfunction of the pancreas, potentially resulting in diabetes. 66 This pancreas insufficiency-related diabetes, type 3c diabetes, is insulin-dependent and may be misclassified as T1D. 67 Pancreatitis and fractures share alcohol abuse as a risk factor, 66 and pancreatitis is strongly linked to fracture risk (3.5 fold increased risk of a hip fracture). 68 The increased risk of fracture in patients with T1D may thus be partly explained by misclassification, comorbidities, and complications. However, current evidence neither confirm nor reject that comorbidities and complications in T1D may contribute to the observed fracture risk. Further large-scale cohort studies should investigate the influence of these conditions on fracture risk.
Impact of Medications on Fracture Risk
The medications used to treat T1D may influence fracture risk. Treatment of patients with T1D is based mainly on insulin, and a recent registry-based study found no effect of insulin dose on fracture risk in patients with T1D. 10 However, in that study, hypoglycemic events increased fracture risk by 1.58 fold. 10 Other studies have reported increased risk of fractures due to hypoglycemic events, 69, 70 whereas other studies found no association. 9, 52, 53 Although evidence on hypoglycemia and fracture is conflicting, hypoglycemia is associated with falls 61 and hypoglycemia may be widely underdiagnosed in studies that mainly use registries and questionnaires. Thus, the true prevalence of fractures due to hypoglycemia is susceptible to be larger than what is presented in the literature.
Patients with T1D are frequent users of antihypertensives and lipid lowering drugs (e.g. statins).
Antihypertensives may induce orthostatic hypotension and thereby falls, which could increase fracture risk. Diuretics may also increase the loss of minerals (e.g. calcium and magnesium) by urinary excretion. In patients with diabetes, loop diuretics but not thiazides are associated with an increased risk of fracture. 71 A post-hoc prospective evaluation of the randomized controlled trial (RCT) "Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial" showed a decreased fracture rate in individuals treated with thiazide diuretics compared to angiotensin converting enzyme inhibitors (ACEi). 72 In meta-analyses of observational studies, loop diuretics and ACEi are associated with an increased fracture risk compared to non-users. 73, 74 Although these studies are not restricted to patients with diabetes; antihypertensives are linked to fractures and may especially induce fracture in patients with low BMD as in T1D. Although antihypertensives may have adverse effects on bone health, they should not be disregarded due to the large benefit in the prevention of cardiovascular disease in patients with T1D. The current evidence can neither reject nor confirm that drugs used for the treatment of T1D influence the observed fracture risk.
Perspectives
T1D is related to an increased risk of fracture, especially hip fracture. Vertebral fractures seem more common in T1D although the evidence is sparse. This is a societal health issue as vertebral fractures and hip fractures are associated with an increased mortality risk caused mainly by cardiovascular disease. 75, 76 BMD deficits are observed in T1D, however these do not fully explain the increased fracture risk in T1D. The International Osteoporosis Foundation has suggested a threshold for osteoporosis treatment at T-score <-2.0 for patients with diabetes aged 50 or with risk factors for fracture, whereas it is −2.5 for other individuals, 77 however there is no specific evidence that support early intervention with BMD improvement and prevention of osteoporosis and this recommendation is based on the observed fracture rates and BMD deficits. Based on current knowledge, antiosteoporotic drugs are as efficient in patients with T1D as in individuals without diabetes, although evidence is sparse and mainly from observational studies and posthoc analyses of RCTs. 78 Vitamin D supplementation may be beneficial in T1D due to lower levels of vitamin D compared with individuals without diabetes. However, a systematic review reported that there is insufficient data on the effect of vitamin D intake, calcium intake, and physical activity on bone health in T1D. 79 Thus, vitamin D and calcium supplementation in T1D should follow national guidelines. Many patients with T1D are fearful of falls, and treatment with antihypertensives, hypoglycemia, and diabetes complications may lead to falls. Table 1 displays efforts to detect increased fracture risk and prevent fractures in patients with T1D. Hypoglycemic events may be reduced by continuous glucose monitoring which is highlighted by the closed loop insulin delivery system that reduces hypoglycemic events compared to sensor-augmented pump. 80, 81 Although current evidence is conflicting, a fall prevention strategy may reduce fracture rates in T1D and implementation of such efforts should be at large scale to detect potential benefits.
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